Ribo Life Science Unveils RiboPepSTAR™ for Targeted siRNA Delivery Across Multiple Organs
Suzhou Ribo Life Science Co., Ltd., commonly known as Ribo, has made headlines recently by presenting its groundbreaking RiboPepSTAR™ technology during the RNA Leaders Europe Conference in Vienna, Austria, on March 19, 2026. This advanced platform signifies a crucial step forward in the company's ongoing quest to expand the reach of RNA therapies beyond the liver and target multiple organs effectively.
The introduction of RiboPepSTAR™ follows the success of RiboGalSTAR™, which has already supported seven clinical programs and facilitated global partnerships exceeding USD 6 billion in value. This background has laid the groundwork for Ribo's ambitious goal to develop extra hepatic and multi-target platforms.
One of the most notable achievements utilizing RiboPepSTAR™ is its effectiveness in targeting kidney tissues. Preclinical studies demonstrate a remarkable selective uptake of siRNA in proximal tubular cells across various models. In fact, it has achieved up to 80% target gene knockdown—from rodents to non-human primates, which indicates a robust potential for addressing kidney-related ailments. The physiological proof of concept was confirmed in multiple disease models, including a type 2 diabetes model, underscoring its efficacy in reducing target-related biomarkers significantly. Additionally, the first kidney-targeted drug developed by Ribo has already entered the IND-enabling phase, indicating a step closer to clinical application.
In another exciting development, Ribo's technology has shown promising results in cardiac applications. A cardiac targeting conjugate achieved sustained knockdown in heart tissue within a mouse model. The experiments yielded minimal effects on surrounding muscle and negligible activity in the liver and kidneys, affirming RiboPepSTAR™'s specificity for cardiac cells—crucial for addressing heart diseases effectively.
RiboPepSTAR™ has not only been groundbreaking in kidney and heart applications but has also demonstrated significant potential in targeting adipose tissue. Trials in non-human primates resulted in an impressive 96% knockdown rate, further supporting the technology's versatility in treating metabolic disorders.
Moreover, Ribo is simultaneously advancing its multi-target siRNA platform, which allows a single molecular entity to silence two or more genes at once. This innovative approach is not only poised to achieve knockdown levels comparable to those of single-target molecules but also offers the promise of synergistic modulation of biological pathways, enhancing therapeutic benefits.
Ribo's strategic focus on its proprietary extra hepatic and multi-targeting platforms signifies a pivotal moment in siRNA-based therapy. By enabling targeted delivery across various organs, these innovations are expected to unlock new avenues for the treatment of renal, cardiac, and metabolic disorders. This ambitious vision aligns with Ribo's commitment to delivering next-generation siRNA medicines to patients around the globe, revolutionizing the landscape of therapeutic solutions.
As Ribo continues to push the limits of RNA delivery technologies, the ongoing development and validation of RiboPepSTAR™ could potentially lead to transformative advancements in how complex diseases are treated. This marks not just a win for Ribo but a significant milestone in the battle against challenging medical conditions affecting millions worldwide.
With these advancements, the future looks promising as Ribo Life Science endeavors to lead in the RNA therapeutic space, and RiboPepSTAR™ is setting the stage for a new era in drug development and delivery.
Building on Successful Foundations
The introduction of RiboPepSTAR™ follows the success of RiboGalSTAR™, which has already supported seven clinical programs and facilitated global partnerships exceeding USD 6 billion in value. This background has laid the groundwork for Ribo's ambitious goal to develop extra hepatic and multi-target platforms.
Targeting the Kidney
One of the most notable achievements utilizing RiboPepSTAR™ is its effectiveness in targeting kidney tissues. Preclinical studies demonstrate a remarkable selective uptake of siRNA in proximal tubular cells across various models. In fact, it has achieved up to 80% target gene knockdown—from rodents to non-human primates, which indicates a robust potential for addressing kidney-related ailments. The physiological proof of concept was confirmed in multiple disease models, including a type 2 diabetes model, underscoring its efficacy in reducing target-related biomarkers significantly. Additionally, the first kidney-targeted drug developed by Ribo has already entered the IND-enabling phase, indicating a step closer to clinical application.
Innovations in Cardiac Targeting
In another exciting development, Ribo's technology has shown promising results in cardiac applications. A cardiac targeting conjugate achieved sustained knockdown in heart tissue within a mouse model. The experiments yielded minimal effects on surrounding muscle and negligible activity in the liver and kidneys, affirming RiboPepSTAR™'s specificity for cardiac cells—crucial for addressing heart diseases effectively.
Adipose Tissue Targeting
RiboPepSTAR™ has not only been groundbreaking in kidney and heart applications but has also demonstrated significant potential in targeting adipose tissue. Trials in non-human primates resulted in an impressive 96% knockdown rate, further supporting the technology's versatility in treating metabolic disorders.
Multi-Target siRNA Platform
Moreover, Ribo is simultaneously advancing its multi-target siRNA platform, which allows a single molecular entity to silence two or more genes at once. This innovative approach is not only poised to achieve knockdown levels comparable to those of single-target molecules but also offers the promise of synergistic modulation of biological pathways, enhancing therapeutic benefits.
Commitment to Next-Generation Therapies
Ribo's strategic focus on its proprietary extra hepatic and multi-targeting platforms signifies a pivotal moment in siRNA-based therapy. By enabling targeted delivery across various organs, these innovations are expected to unlock new avenues for the treatment of renal, cardiac, and metabolic disorders. This ambitious vision aligns with Ribo's commitment to delivering next-generation siRNA medicines to patients around the globe, revolutionizing the landscape of therapeutic solutions.
As Ribo continues to push the limits of RNA delivery technologies, the ongoing development and validation of RiboPepSTAR™ could potentially lead to transformative advancements in how complex diseases are treated. This marks not just a win for Ribo but a significant milestone in the battle against challenging medical conditions affecting millions worldwide.
With these advancements, the future looks promising as Ribo Life Science endeavors to lead in the RNA therapeutic space, and RiboPepSTAR™ is setting the stage for a new era in drug development and delivery.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.